Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ferritin | 0.0008 | 0.5 | 0.5 |
Treponema pallidum | bacterioferrin (TpF1) | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | apoferritin-2 | 0.0008 | 0.5 | 0.5 |
Trichomonas vaginalis | ferritin, putative | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | apoferritin-2 | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.0008 | 0.5 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrA | 0.0008 | 0.5 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrB | 0.0008 | 0.5 | 0.5 |
Echinococcus multilocularis | ferritin | 0.0008 | 0.5 | 0.5 |
Echinococcus multilocularis | expressed protein | 0.0008 | 0.5 | 0.5 |
Echinococcus granulosus | ferritin | 0.0008 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable bacterioferritin BfrA | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.0008 | 0.5 | 0.5 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.0008 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Bacterioferritin BfrB | 0.0008 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | bacterioferritin/cytochrome b1 | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.0008 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.0008 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.